CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Slides:

Advertisements

Similar presentations

Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.

Advertisements

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

(p for noninferiority = 0.01)

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:

(CMR vs. guidelines, p < 0.001)

(p < for group 1 or 2 vs. group 3)

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Figure 2 Cumulative proportion of patients experiencing a seizure recurrence after randomization, comparing immediate vs deferred treatment Cumulative.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

(p for noninferiority = )

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

Losartan vs. Atenolol in Marfan Syndrome

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

Modified Rankin score 0-2

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension Bodo Cremers,

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p < 0.05 for paclitaxel angioplasty vs. either control)

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

(p < for noninferiority)

Anaerobic threshold responder analysis

(p for noninferiority < 0.001)

(p = for noninferiority)

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Maria R. Costanzo et al. JCHF 2016;4:

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

HF-Related Hospitalization and Readmissions

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

(p for noninferiority = 0.01)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

MATRIX: Radial vs. Femoral

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so that providers received daily pulmonary artery pressure information for 6 months (n = 270) vs. control (n = 280). Results (p = 0.0002) Hospitalization for heart failure: 0.32 events per patient per 6 months in the treatment group vs. 0.44 events per patient per 6 months in the treatment group (p = 0.0002) During the open access period, control patients experienced a 48% reduction in hospitalization for heart failure compared with control patients during the randomization period (p < 0.0001) 0.44 0.32 Events/patient Conclusions Among individuals with recent hospitalization for heart failure, the use of an implantable device to provide daily pulmonary artery hemodynamic information was beneficial This device resulted in a reduction in hospitalization for heart failure Pulmonary artery monitoring Control Abraham WT, et al. Lancet 2016;387:453-61